UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
(Amendment No. )
|
|
|
|
|
|
☒ Filed by the Registrant
|
|
|
☐ Filed by a Party other than the Registrant
|
|
|
|
|
|
|
|
|
|
|||
|
|
Check the appropriate box:
|
|
|||
|
|
☐
|
|
|
Preliminary Proxy Statement
|
|
|
|
☐
|
|
|
CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED
BY RULE 14a-6(e)(2))
|
|
|
|
☐
|
|
|
Definitive Proxy Statement
|
|
|
|
☒
|
|
|
Definitive Additional Materials
|
|
|
|
☐
|
|
|
Soliciting Material Under Rule §240.14a-12
|
|
|
|
|
|
|
|
|
|
|
|
ROYALTY PHARMA PLC
|
|
(Name of Registrant as Specified In Its Charter)
|
|
|
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
|
|
|
|
|
|
|
|||
|
|
Payment of Filing Fee (Check the appropriate box):
|
|
|||
|
|
☒
|
|
|
No fee required.
|
|
|
|
☐
|
|
|
Fee paid previously with preliminary materials.
|
|
|
|
☐
|
|
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
14a-6(i)(1) and 0-11.
|
|
|
|
|
|
|
|
|
